NCCN Guidelines® recommend fedratinib (INREBIC®) as an initial treatment option (Category 1) for patients with higher-risk (intermediate-2 or high-risk) MF who have platelet counts ≥50 × 109/L.

*NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Patients who are not transplant candidates.

NCCN Guidelines® recommend fedratinib (INREBIC®) as an initial treatment option (Category 1) for patients with higher-risk (intermediate-2 or high-risk) MF who have platelet counts ≥50 × 109/L.

*NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
Patients who are not transplant candidates.

This website is best viewed
using the horizontal display on
your tablet device.

This website is best viewed
using the vertical display on
your mobile device.